In this study, the synthesis, in vitro anti-Candida activity and molecular modeling of 4-phosphorylated derivatives of 1,3-oxazole as inhibitors of Candida albicans fructose-1,6-bisphosphate aldolase (FBA-II) are demonstrated and discussed.
Introduction
Fungal infections are the important problems of modern world healthcare system. Candidiasis is the main systemic human infection. Candida spp. is an opportunistic pathogen causing serious pathology in patients with impaired immunity. Candida spp. can lead to severe systemic infections and to mortality in patients with various types immunodeficiency [1, 2] .
Modern anti-Candida drugs include such antifungal agents as azoles, echinocandins, polyenes and flucytosine (5-FC) [3] . Echinocandins inhibit the synthesis of b-glucan [4] . Polyenes (amphotericin B) act by creating of the complexes with ergosterol of the plasma membrane [5] . Flucytosine blocks the DNA synthesis, leading to the disruption to DNA replication [6] . Azoles are the most numerous antifungal agents known since the 1960s [7] . Azoles are completely synthetic compounds, classified as imidazoles and triazoles and are the rapidly developing group of antifungal compounds. The sterol 14a-demethylase (CYP51) is the azoles target in which the five-membered azole ring forms a coordination bond with iron heme by inhibiting the ergosterol biosynthesis. Rapid formation of Candida spp. multidrug resistance is the ground for the drugs development with new alternative targets. In our opinion, fructose-1,6-bisphosphate aldolase is a promising target for the development of new antifungal agents.
Its known, fructose-1,6-bisphosphate aldolase (FBA-II, EC4.1.2.13) is an important enzyme of glycolysis, gluconeogenesis and the Calvin cycle. This class II enzyme is a zinc-containing protein that catalyzes the reversible cleavage of fructose-1,6-bisphosphate (FBP) to dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate (GAP) [8] . The FBA-II uses a bivalent zinc ion to polarize and stabilize the ketocarbonyl group of the substrate and its intermediate enediolate. FBA-II is present in pathogenic microbes -fungi, bacteria and parasites but is absent in higher plants and mammals that make it a convenient selective target for the development of new antifungal agents [9] . The studies of this enzyme inhibitors for various organisms, including M. tuberculosis [10] , Bacillus subtilis [11] , Pseudomonas aeruginosa [12] and Streptococcus pneumoniae [13] are known. Rodaki A. et al. [9] studied the depletion effect of C. albicans FBA-II as an antifungal drugs target.
These results showed that an enzyme level decrease to less than 5% causes the C. albicans growth inhibition. A number of substrate-like FBA-II inhibitors have been developed, however, they did not provide an adequate level of structural specificity required for effective drug-candidates [9] .
In our work we represent the in silico study, synthesis and antifungal evaluation of series 4-phosphorylated derivatives of 1,3-oxazoles with antifungal special mechanism of action as perspective candidates of new antifungal agents against C. albicans.
Materials and methods

Chemistry
The IR spectra of substances were registered (KBr disks) by using Bruker VERTEX 70 FT-IR spectrometer (Bruker, Rheinstetten, Germany). 1 Synthesis of 1-[4-(diethoxyphosphoryl)-2-methyl-1,3-oxazol-5-yl]piperidin-4-ylcarboxylic acid 1, and also acids, needed for syntheses of appropriate sodium salts 2 and 3 is shown on Scheme 1 [14] . Synthesis of sodium salts 4e6 has been previously reported [15] . Their precursors e diethyl 5-arylsulfanyl-2-(4-methylphenyl)-1,3-oxazol-4-ylphenylphosphonates e were prepared according to the previously described method (Scheme 2).
Disodium salt of 5-(4-chlorophenylsulfanyl)-2-(4-methylphenyl)-1,3-oxazol-4-ylphosphonic acid 4 was prepared by evaporation to dryness under a reduced pressure of mixture aqueous solution of 1 mmol 5-(4-chlorophenylsulfanyl)-2-(4-methylphenyl)-1,3-oxazol-4-ylphosphonic acid and 2 mmol of sodium bicarbonate which used without further purification for biological tests. 
Antifungal activity
The fungi C. albicans M885 (ATCC 10231) and its clinical isolate were used as tested microorganisms. The strains were subcultured on Sabouraud agar in Petri plates according to the manufacturer's instructions. The standard agar disk diffusion method [16] was performed to evaluate anti-Candida property of studied com- 
Protein model creation and validation
SWISSMODEL server [20] was used for FBA-II C. albicans sequence (UniProt: Q9URB4) modeling. First, a preliminary search for evolutionarily related sequences was performed using the SWISS-MODEL Template Library. The searching was conducted by BLAST [21] and HHBlits [22] for structures analysis of similar to FBA-II C. albicans sequence. Secondly, homology models were created based on the results ranking of the templates. The homology models quality validation of FBA-II C. albicans was conducted by ERRAT and PROCHECK. ERRAT [23] was used for the unrelated interactions statistic between different atoms types and error function value graphs in comparison with the position of the sliding window with 9 residues, calculated considering the highly purified structures statistic. PRO-CHECK was used for the stereochemical quality verification of a protein structure by analyzing residue-by-residue geometry and overall structure geometry [24] .
Molecular docking
Minimized and validated model FBA-II C. albicans was used for the protein-ligand docking studies. The molecular docking was conducted similar to our earlier works [25, 26, 27] . The docking compatible structures of the protein, ligands and grid box creation were made by using AutoDock Tools (ADT) (ver.1.5.6) [28] .The structure of FBA-II A-subunit was selected and stored as a PDB file by Accelrys DS (ver.
2.5.5) [29] . All protein hydrogens were added using ADT and no Bond Order method and the macromolecule atoms were renumbered including the new hydrogens. The partial charges were calculated and added by using Gasteiger method and the prepared protein structure was saved in PDBQT format.
The structures and conformations of studied ligands were created by using ChemAxon Marvin Sketch 5.3.735 [30] and were saved in Mol2 format. The optimization of the ligands structures and energy minimization were performed by software Avogadro v1.1.1 [31] . We used the "Auto Optimization Tool" by applying the MMFF94s force field and the steepest descent algorithm. Partial charges and torsions angles of ligands were changed by ADT and the ligand structures were saved as the resulting files in PDBQT format.
The prepared protein structure and optimized ligands were used for the conduction of docking simulations by AutoDock 4.2 [32] . Lamarckian genetic algorithm method and standard docking procedure for the rigid protein were used. The ADT was used to generate of the docking parameter files and both grid. Zn atom was set as the box center. The grid map of 50*50*50 points with grid spacing of 0.375 A was used and the settings for other parameters were applied by default.
The molecular docking time of one ligand was about 30 min. All operations were made on Windows XP SP3 computer with an Intel Core i3 CPU (3.20 GHz) and 2 GB of RAM. The software package Accelrys DS was used for illustration and to analyze the proteineligand interactions.
Results and discussion
Our assumption about the phosphonates contained inhibitors of FBA-II C. albicans is confirmed by the existence of FBP, DHAP and PGH analogues with high inhibitory activity to this enzyme [33] . It should also be noted that one of the most studied FBA-II is the FBA-II M. tuberculosis [34] . 
Alignment of FBA-II C. albicans and FBA-II M. tuberculosis protein sequences
Structural analogy was used for the development of FBA-II C. albicans inhibitors.
FBA-IIs C. albicans and M. tuberculosis were analyzed using Protein BLAST (NCBI) -Needleman-Wunsch Global Align Protein Sequences [19] . Sequences of FBA-II C. albicans and FBA-II M. tuberculosis were used for comparing in accordingly to the substitution Matrix (BLOSUM-62) and Gap Costs (11,1) operating parameters (Fig. 1 ).
The obtained results ( Fig. 1 ) indicate about the significant enzymes similarity of the organisms. So, the sequence identities was 41%, the sequence similarity was 55%
and a number to gaps was 9%. These results confirmed the high similarity of enzyme primary structures.
The secondary structure similarity, the binding sites and the active sites of FBA-IIs were analyzed by Accelrys DS (Fig. 2) . Fig. 2 has demonstrated a significant similarity not only primary but also secondary structure of enzymes. The similarity is noted in the area of metal binding sites, active sites and DHAP, GAP binding sites.
Thus, the established significant similarity of enzyme structures assumes the inhibitors structural similarity.
Development of FBA-II C. albicans inhibitors
The BioAssay 588726 was used as BioAssay with the greatest number of FBA-II M. tuberculosis inhibitors e 8221 compounds. Analysis of inhibitor structures by Chemaxon Instant JChem [38] allowed to identify 333 inhibitors as 1,3-oxazole derivatives and 25 compounds as 1,3-oxazole-4-phosphonate derivatives (Fig. 3) .
Thus, it is established, that 25 FBA-II M. tuberculosis inhibitors contains the 1,3-oxazole-4-phosphonate moiety in the structure (Fig. 4) . So, design of FBA-II C. albicans inhibitors was performed by analogy of FBA-II M. tuberculosis inhibitors containing this moiety. One group of 1,3-oxazole-4-phosphonates inhibitors was modified at the C2 position to make 2-methyl-and 2-methylphenyloxazole give 2-methylbenzoxazoles and at the C5 position to form 5-methylphenylsulfonyl and 5-chlorophenylsulfanyl derivatives. Designed compounds 1e6 were synthesized for biologycal testing (Fig. 5 ).
Antifungal evaluation
Anti-Candida activity results of the studied compounds against fungi C. albicans M885 (ATCC 10231) and fluconazole (FCZ) resistance C. albicans clinical isolate are presented in Table 1 . Table 1 shows that all studied compounds had fluconazole-like activity against C. albicans M885 (ATCC 10231) in both applicable concentration. Activity of the studied compounds in applicable concentrations 2,0 mN against C. albicans clinical isolate as the diameters of inhibition zone around the all compounds disks didn't We have assumed that the inhibiting action mechanism of 4-phosphorylated derivatives of 1,3-oxazole against the fluconazole-resistant C. albicans clinical isolate strain can be connected not with 14a-demethylase inhibition like an flukonazol, but with other fungal molecular target.
Protein modelling
Creating of FBA-II C. albicans homology 3D model
The preliminary search of the FBA-II related sequences was performed using SWISS-MODEL Template Library and 36 templates were created (Supplementary Material). 10 templates (Fig. 6 ) with a sequence identity above 49% were selected and 10 models were built based on this templates (Table 2 ).
Based on the sequence identity value, QSQE and resolution, three most significant enzyme models such as #10 (3qm3. 
Quality evaluation of the built FBA-II C. albicans homology 3D model
The quality estimation of the model #10 selected as optimal FBA-II C. albicans model was conducted by using ERRAT and PROCHECK. ERRAT-web server results showed the high model quality. The overall quality factor for the subunit A was 98.780 and for the subunit B was 97.953 ( Figs. 10 and 11 ). PROCHECK-web server data analysis has been also confirmed the 3D model structure FBA-II good quality by using Ramachandran plot analysis (Fig. 12) .
Ramachandran plot results indicated that 92.3 % of the protein residues were distributed in the favored regions, 7.2 % -in the additionally allowed regions, 0.5 % -in the generously allowed regions and the absent of residues in the disallowed region. Thus, the created 3D structure of FBA-II S. albicans is adequate and can be used for the molecular docking.
Molecular docking
Molecular docking of the compounds 1e6 to the active site of FBA-II S. albicans were performed for mechanism interpretation of the high antifungal activity of studied compounds.
Identification of FBA-II C. albicans inhibitors binding modes
The similarity of the protein structure of FBA-II C. albicans and FBA-II M. tuberculosis was used for searching binding site of the studied compounds. The obtained Fig. 7 . Quality of the built model #10. sequence identity indicator (41%) and sequence similarity indicator (55%) (Fig. 1) confirm the significant similarity of protein structures of enzymes, analogically to Han X. et al. [33] . To search of the enzyme inhibitors optimal binding center, a number of FBA-II M. tuberculosis crystallographic structure [34, 39] Molecular docking of ligand 3 (Fig. 13) to the active site of FBA-II showed that the phosphonate group forms three electrostatic bonds of length 5.12 A, 4.02 A and 4.82 A with a catalytic zinc atom and amino acid residues His110 (Pi-anion) and Asp144, and two hydrogen bonds of length 3.64 A and 2.83 A with amino acid residues Gly227 and Val228.
The oxazole ring forms an electrostatic Pi-anion bond of length 3.18 A with amino acid residue Asp144, and a hydrophobic Pi-alkyl bond of length 5.35 A with Ala112. There are also two hydrophobic (alkyl and Pi-sigma) bonds of length 3.50 A and 4.88 A between the aromatic ring and ring methyl group and the Ala112 and Leu145.
Molecular docking of ligand 4 (Fig. 14) to the enzyme binding site demonstrates the formation of five electrostatic bonds with phosphonate moiety of length 1.75 A, 3.55 A, 3.57 A, 3.62 A, 4.04 A with a catalytic zinc atom, His110, Asp144 and of one hydrogen bond of length 2.60 A with amino acid residue His226. Fig. 11 . The 3D profile of subunit B FBA-II C.albicans verified by using ERRAT server. Molecular docking of compounds 1 and 2 into the C. albicans FBA-II active center showed the formation of low-energy ligand-protein complexes and ligands localization at long distance from the catalytic zinc atom (>6 A). Therefore, based on the significant structural similarity and similarity of the level of anti-Candida activity of compounds 1e3, it was suggested that the hydrolysis of dialkylphosphonates 1 and 2 to monoalkylphosphonates in the course of interaction with the C. albicans enzyme system is possible [42, 43, 44, 45, 46] . Thus, compounds 1 and 2 were docked as monoesters. Molecular docking of compound 2 as a monoalkylphosphonate has demonstrated the results similar to the compound 3 (Fig. 13 ).
Molecular docking of ligand 1 (Fig. 17) The result of the molecular docking of all ligands has shown that all tested compounds has common type of interaction with the catalytic center of the enzyme through the phosphonate group. High stability of ligand-protein complexes formed by compounds 1e6 with binding energy DG ¼ e6.89, e7.2, e7.16, e7.5, e8.0, e7.9 kcal/mol respectively is demonstrated. The amino acid residues His110, His226, Gly227, Leu248, Val238, Asp144, Lys230, Glu174, Glu147, Gly227, Ala112, Leu145 and catalytic zinc atom performs the key role in the binding of these compounds in the FBA-II active site C. albicans.
Conclusions
The synthesis, in vitro antifungal activity and molecular modelling of 4-phosphorylated derivatives of 1,3-oxazole as inhibitors of C. albicans fructose-1,6-bisphosphate aldolase were performed and discussed.
The structure similarity of FBA-II C. albicans and FBA-II M. tuberculosis was the basis of the strategy for the design of new anti-Candida agents as fructose-1,6-bisphosphate aldolase inhibitors.
A significant similarity of the FBA-II C. albicans and FBA-II M. tuberculosis is shown using NCBI Protein BLAST with the application of Needleman-Wunsch Global Align Protein Sequences. Also, a similarity of secondary structure, metal binding sites, active sites and substrate binding sites of these enzymes were demonstrated by DS.
FBA-II C. albicans inhibitors were developed and synthesized based on the structure similarity of FBA-II M. tuberculosis inhibitors contained 1,3-oxazole-4-phosphonates moiety.
The experimental studies of the anti-Candida activity shown the high antifungal potential of studied compounds against C. albicans M885 (ATCC 10231). The established growth inhibition of fluconazole-insensitive clinical isolate was connected with fructose-1,6-bisphosphate aldolase inhibition. To confirm the proposed action mechanism FBA-II C. albicans homology model was created using the SWISS-MODEL server. High quality of the created homology model was confirmed by using ERRAT and PROCHECK.
The presumed mechanism of inhibition by studied compounds was demonstrated using molecular docking into the active site of FBA-II C. albicans homology model.
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